ISSN 2736-1748
African Journal of AIDS and HIV Research ISSN 2326-2691 Vol. 7 (1), pp. 001-004, January, 2019. © International Scholars Journals
Case Report
Safe use of Sunitinib in metastatic non-clear cell renal cell cancer in the setting of human immunodeficiency virus
Govender P. S.* and Abdel Goad E. H.
P. O. Box 3019, Sunningdale, Durban, 4019 South Africa.
Accepted 04 July, 2018
Abstract
The introduction of targeted therapies has offered the promise of better survival outcomes for patients with metastatic renal cell carcinoma. Sunitinib malate, an oral, multitargeted tyrosine kinase inhibitor, is an important treatment option for patients with metastatic renal cell carcinoma. This case study explores the controversial use of sunitinib in a patient with a non-clear cell variant of renal cell carcinoma, also on treatment with combined antiretroviral treatment for a co-existing human immunodeficiency virus infection.
Key words: Sunitinib, non-clear cell metastatic renal cell carcinoma, human immunodeficiency virus and antiretroviral treatment.